Literature DB >> 23892905

T-cell receptor signaling in peripheral T-cell lymphoma - a review of patterns of alterations in a central growth regulatory pathway.

Kathrin Warner1, Nicole Weit, Giuliano Crispatzu, Joan Admirand, Dan Jones, Marco Herling.   

Abstract

T-cell receptor (TCR) signaling is pivotal in T-cell development and function. In peripheral T-cell lymphomas/leukemias (PTCL/L), histogenesis, transforming events, epidemiology, and clinical presentation are also closely linked to TCR-mediated influences. After reviewing the physiology of normal TCR signaling and cellular responses, we describe here the association of subgroups of PTCL/L with specific patterns of TCR activation as relevant tumor-initiating and/or tumor-sustaining programs. We identify PTCL/L with a functionally intact TCR machinery in which stimulation is possibly incited by exogenous antigens or autoantigens. Distinct from these are tumors with autonomous oncogenic signaling by dysregulated TCR components uncoupled from extrinsic receptor input. A further subset is characterized by transforming events that activate molecules acting as substitutes for TCR signaling, but triggering similar downstream cascades. We finally discuss the consequences of such a functional model for TCR-targeted therapeutic strategies including those that are being tested in the clinic and those that still require further development.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23892905     DOI: 10.1007/s11899-013-0165-2

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  51 in total

Review 1.  The TCR-mediated signaling pathways that control the direction of helper T cell differentiation.

Authors:  Toshinori Nakayama; Masakatsu Yamashita
Journal:  Semin Immunol       Date:  2010-05-21       Impact factor: 11.130

2.  Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia.

Authors:  Marcin W Wlodarski; Christine O'Keefe; Evan C Howe; Antonio M Risitano; Alexander Rodriguez; Ilka Warshawsky; Thomas P Loughran; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2005-05-24       Impact factor: 22.113

3.  Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 bias.

Authors:  Suzanne M Morgan; Elizabeth Hodges; Tracey J Mitchell; Susan Harris; Sean J Whittaker; John L Smith
Journal:  J Invest Dermatol       Date:  2006-06-01       Impact factor: 8.551

Review 4.  Plasticity of CD4+ T cell lineage differentiation.

Authors:  Liang Zhou; Mark M W Chong; Dan R Littman
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

5.  Monoclonal TCR-Vbeta13.1+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin.

Authors:  Pilar Garrido; Francisco Ruiz-Cabello; Paloma Bárcena; Yorick Sandberg; Julia Cantón; Margarida Lima; Ana Balanzategui; Marcos González; Miguel Angel López-Nevot; Anton W Langerak; Andrés C García-Montero; Julia Almeida; Alberto Orfao
Journal:  Blood       Date:  2007-02-15       Impact factor: 22.113

6.  Polymerase chain reaction amplification analyses of clonality in T-cell malignancy including peripheral T-cell lymphoma.

Authors:  E Hodges; S E Edwards; W M Howell; J L Smith
Journal:  Leukemia       Date:  1994-02       Impact factor: 11.528

7.  High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Michael A Teitell; Marina Konopleva; Farhad Ravandi; Ryuji Kobayashi; Dan Jones
Journal:  Blood       Date:  2007-09-21       Impact factor: 22.113

8.  Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.

Authors:  A L Feldman; D X Sun; M E Law; A J Novak; A D Attygalle; E C Thorland; S R Fink; J A Vrana; B L Caron; W G Morice; E D Remstein; K L Grogg; P J Kurtin; W R Macon; A Dogan
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

Review 9.  Homeostasis of naive and memory T cells.

Authors:  Charles D Surh; Jonathan Sprent
Journal:  Immunity       Date:  2008-12-19       Impact factor: 31.745

Review 10.  IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets.

Authors:  Sven Létourneau; Carsten Krieg; Giuseppe Pantaleo; Onur Boyman
Journal:  J Allergy Clin Immunol       Date:  2009-04       Impact factor: 10.793

View more
  17 in total

1.  Progression of AITL-like tumors in mice is driven by Tfh signature proteins and T-B cross talk.

Authors:  Mariko Witalis; Jinsam Chang; Ming-Chao Zhong; Yasser Bouklouch; Vincent Panneton; Joanna Li; Thorsten Buch; Seok Jin Kim; Won Seog Kim; Young Hyeh Ko; André Veillette; Woong-Kyung Suh
Journal:  Blood Adv       Date:  2020-03-10

2.  Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Authors:  E I Andersson; S Pützer; B Yadav; O Dufva; S Khan; L He; L Sellner; A Schrader; G Crispatzu; M Oleś; H Zhang; S Adnan-Awad; S Lagström; D Bellanger; J P Mpindi; S Eldfors; T Pemovska; P Pietarinen; A Lauhio; K Tomska; C Cuesta-Mateos; E Faber; S Koschmieder; T H Brümmendorf; S Kytölä; E-R Savolainen; T Siitonen; P Ellonen; O Kallioniemi; K Wennerberg; W Ding; M-H Stern; W Huber; S Anders; J Tang; T Aittokallio; T Zenz; M Herling; S Mustjoki
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

3.  Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.

Authors:  S Spinner; G Crispatzu; J-H Yi; E Munkhbaatar; P Mayer; U Höckendorf; N Müller; Z Li; T Schader; H Bendz; S Hartmann; M Yabal; K Pechloff; M Heikenwalder; G L Kelly; A Strasser; C Peschel; M-L Hansmann; J Ruland; U Keller; S Newrzela; M Herling; P J Jost
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

4.  Downmodulation of tumor suppressor p53 by T cell receptor signaling is critical for antigen-specific CD4(+) T cell responses.

Authors:  Masashi Watanabe; Kyung Duk Moon; Melanie S Vacchio; Karen S Hathcock; Richard J Hodes
Journal:  Immunity       Date:  2014-05-01       Impact factor: 31.745

Review 5.  Calling in SYK: SYK's dual role as a tumor promoter and tumor suppressor in cancer.

Authors:  Mariya O Krisenko; Robert L Geahlen
Journal:  Biochim Biophys Acta       Date:  2014-11-04

6.  Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.

Authors:  Yiming Zhong; Shuai Dong; Ethan Strattan; Li Ren; Jonathan P Butchar; Kelsey Thornton; Anjali Mishra; Pierluigi Porcu; J Michael Bradshaw; Angelina Bisconte; Timothy D Owens; Erik Verner; Ken A Brameld; Jens Oliver Funk; Ronald J Hill; Amy J Johnson; Jason A Dubovsky
Journal:  J Biol Chem       Date:  2015-01-15       Impact factor: 5.157

7.  Interleukin-2-inducible T-cell kinase (ITK) targeting by BMS-509744 does not affect cell viability in T-cell prolymphocytic leukemia (T-PLL).

Authors:  Sabine Dondorf; Alexandra Schrader; Marco Herling
Journal:  J Biol Chem       Date:  2015-04-17       Impact factor: 5.157

8.  Targeted cellular immunotherapy for T cell malignancies.

Authors:  Teresa Palomero; Adolfo Ferrando
Journal:  Nat Med       Date:  2017-12-07       Impact factor: 53.440

9.  RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis.

Authors:  Jose R Cortes; Alberto Ambesi-Impiombato; Lucile Couronné; S Aidan Quinn; Christine S Kim; Ana C da Silva Almeida; Zachary West; Laura Belver; Marta Sanchez Martin; Laurianne Scourzic; Govind Bhagat; Olivier A Bernard; Adolfo A Ferrando; Teresa Palomero
Journal:  Cancer Cell       Date:  2018-02-02       Impact factor: 31.743

10.  Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.

Authors:  S Oberbeck; A Schrader; K Warner; D Jungherz; G Crispatzu; J von Jan; M Chmielewski; A Ianevski; H H Diebner; P Mayer; A Kondo Ados; L Wahnschaffe; T Braun; T A Müller; P Wagle; A Bouska; T Neumann; S Pützer; L Varghese; N Pflug; M Thelen; J Makalowski; N Riet; H J M Göx; G Rappl; J Altmüller; M Kotrová; T Persigehl; G Hopfinger; M L Hansmann; H Schlößer; S Stilgenbauer; J Dürig; D Mougiakakos; M von Bergwelt-Baildon; I Roeder; S Hartmann; M Hallek; R Moriggl; M Brüggemann; T Aittokallio; J Iqbal; S Newrzela; H Abken; M Herling
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.